The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn’s Disease
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Gastroenterology"
DOI: 10.1097/mcg.0000000000001341
Abstract: Background: In Crohn’s disease (CD), 10% to 40% of patients do not respond to anti-tumor necrosis factor-α (TNFα) treatment. Currently, there are no biomarkers with adequate sensitivity to separate responders from nonresponders at an early… read more here.
Keywords: response; tnf treatment; treatment; anti tnf ... See more keywords